JP2022527499A5 - - Google Patents
Info
- Publication number
- JP2022527499A5 JP2022527499A5 JP2021557941A JP2021557941A JP2022527499A5 JP 2022527499 A5 JP2022527499 A5 JP 2022527499A5 JP 2021557941 A JP2021557941 A JP 2021557941A JP 2021557941 A JP2021557941 A JP 2021557941A JP 2022527499 A5 JP2022527499 A5 JP 2022527499A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical product
- mutations
- product according
- poziotinib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826758P | 2019-03-29 | 2019-03-29 | |
| US62/826,758 | 2019-03-29 | ||
| PCT/US2020/025478 WO2020205632A1 (en) | 2019-03-29 | 2020-03-27 | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527499A JP2022527499A (ja) | 2022-06-02 |
| JP2022527499A5 true JP2022527499A5 (https=) | 2023-03-30 |
| JP7700043B2 JP7700043B2 (ja) | 2025-06-30 |
Family
ID=72666271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557941A Active JP7700043B2 (ja) | 2019-03-29 | 2020-03-27 | Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220175778A1 (https=) |
| EP (1) | EP3946632A4 (https=) |
| JP (1) | JP7700043B2 (https=) |
| KR (1) | KR20210145161A (https=) |
| CN (1) | CN113766955A (https=) |
| AU (1) | AU2020256119A1 (https=) |
| BR (1) | BR112021019376A2 (https=) |
| CA (1) | CA3132834A1 (https=) |
| IL (1) | IL286576A (https=) |
| MX (1) | MX2021011925A (https=) |
| PH (1) | PH12021552110A1 (https=) |
| SG (1) | SG11202109531UA (https=) |
| WO (1) | WO2020205632A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3956035A4 (en) * | 2019-04-17 | 2023-01-25 | Board of Regents, The University of Texas System | ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS |
| PY21113397A (es) * | 2020-12-29 | 2022-10-12 | Spectrum Pharmaceuticals Inc | Tratamiento para tumores sólidos malignos |
| CA3264494A1 (en) * | 2022-08-09 | 2024-02-15 | Heligenics Inc. | METHOD FOR EVALUATING THE CLINICAL RELEVANCE OF A GENETIC VARIANCE |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101217526B1 (ko) * | 2010-06-11 | 2013-01-02 | 한미사이언스 주식회사 | 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 |
| KR101317809B1 (ko) * | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| IN2014DN05803A (https=) * | 2011-12-14 | 2015-05-15 | Univ Texas | |
| KR20190015360A (ko) * | 2016-05-31 | 2019-02-13 | 네스텍 소시에테아노님 | Ｈｅｒ2 및 ｈｅｒ3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법 |
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| MX2021007554A (es) * | 2018-12-21 | 2021-08-11 | Univ Texas | Terapia de combinacion para el tratamiento de cancer. |
| KR102477643B1 (ko) * | 2019-05-09 | 2022-12-13 | 주식회사 엘지에너지솔루션 | 전기화학소자용 분리막 및 이를 포함하는 전기화학소자 |
-
2020
- 2020-03-27 MX MX2021011925A patent/MX2021011925A/es unknown
- 2020-03-27 CA CA3132834A patent/CA3132834A1/en active Pending
- 2020-03-27 JP JP2021557941A patent/JP7700043B2/ja active Active
- 2020-03-27 US US17/600,017 patent/US20220175778A1/en active Pending
- 2020-03-27 AU AU2020256119A patent/AU2020256119A1/en not_active Abandoned
- 2020-03-27 BR BR112021019376A patent/BR112021019376A2/pt not_active Application Discontinuation
- 2020-03-27 PH PH1/2021/552110A patent/PH12021552110A1/en unknown
- 2020-03-27 SG SG11202109531UA patent/SG11202109531UA/en unknown
- 2020-03-27 WO PCT/US2020/025478 patent/WO2020205632A1/en not_active Ceased
- 2020-03-27 KR KR1020217032121A patent/KR20210145161A/ko active Pending
- 2020-03-27 EP EP20782979.7A patent/EP3946632A4/en active Pending
- 2020-03-27 CN CN202080032340.6A patent/CN113766955A/zh active Pending
-
2021
- 2021-09-22 IL IL286576A patent/IL286576A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022529945A5 (https=) | ||
| JP2022527788A5 (https=) | ||
| JP2022529016A5 (https=) | ||
| JP2020502059A5 (https=) | ||
| Ponti et al. | BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival | |
| JP2022527499A5 (https=) | ||
| JP2021517894A5 (https=) | ||
| US20190381048A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| JP2019533670A5 (https=) | ||
| JP2019532011A5 (https=) | ||
| WO2017129094A1 (zh) | 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途 | |
| JP2021519306A5 (https=) | ||
| WO2025179058A1 (en) | Pyridopyrimidine derivative as kras g12c inhibitor for the treatment of brain metastasis | |
| JP2022515128A5 (https=) | ||
| Malakar et al. | The role of BRAF inhibitors in the management of ameloblastoma: a literature review | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| CN110840892A (zh) | 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途 | |
| US20230241081A1 (en) | Method for Treating Melanoma | |
| CN113840608B (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP7334194B2 (ja) | Ｔｐ５３突然変異状態及び高頻度突然変異状態に基づくがん治療法 | |
| Grellety et al. | A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy | |
| CN115698338A (zh) | 用妥卡替尼治疗her2突变型癌症的方法 | |
| Yim et al. | The genomic landscape and its clinical implications in hepatocellular carcinoma | |
| US20130005747A1 (en) | Method for selecting a cancer therapy | |
| Higashi et al. | A Case of BRAF-V600E-Positive Pulmonary Pleomorphic Carcinoma Successfully Treated With Dabrafenib and Trametinib Administered via a Percutaneous Endoscopic Gastrojejunostomy Tube for Ileus Caused by Small Intestinal Metastasis |